RxDoctor Payments Data

Tatyana Shekhel, DO

Infectious Disease · Phoenix, AZNPI 1376796599

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,082 of the $1,261 with a category attached, or 85.8%. 7 manufacturers reported payments, led by Merck at 33.7% of the total.

$1,261in general payments, 2019–2025

Across 47 payments — averaging $26.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$425
  • Shionogi Inc$282
  • Insmed, Inc.$208
  • Astellas Pharma US Inc$198
  • Gilead$112
  • Ferring Pharmaceuticals Inc.$21
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$1,08286%
  • Education$17914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,261 in reported general payments places this provider in the 80th percentile of 146 infectious disease providers in Arizona.

See all infectious disease providers in Arizona

Medicare billing

Part B allowed, 2024
$61,894
Medicare patients
113
Services billed
487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala47$231,024
DovatoDolutegravir Sodium/Lamivudine24$67,787
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$52,024
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$38,112
PifeltroDoravirine12$19,861
Daptomycin41$4,933
ErtapenemErtapenem Sodium13$3,058
Ethambutol Hcl16$2,940
Fluconazole31$2,817
Meropenem13$2,280
Methenamine Hippurate19$2,063
Minocycline Hcl14$1,242
Rifampin12$1,060
Cefepime Hcl13$910
Fluconazole-NaclFluconazole In Nacl,iso-Osm14$744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$112$283,04960 claims
MerckPifeltro$425$19,86112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 146 infectious disease providers in Arizona.

Other infectious disease in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →